Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer von Baselga, José, Lewis Phillips, Gail D, Verma, Sunil, Ro, Jungsil, Huober, Jens, Guardino, Alice E, Samant, Meghna K, Olsen, Steve, de Haas, Sanne L, Pegram, Mark D

Volltext

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer von Shah, Manish A., Kang, Yoon-Koo, Thuss-Patience, Peter C., Ohtsu, Atsushi, Ajani, Jaffer A., Van Cutsem, Eric, Hoersch, Silke, Harle-Yge, Marie-Laurence, de Haas, Sanne Lysbet

Volltext

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials von Lambrechts, Diether, Prof, Claes, Bart, MSc, Delmar, Paul, PhD, Reumers, Joke, PhD, Mazzone, Massimiliano, Prof, Yesilyurt, Betül T, MSc, Devlieger, Roland, Prof, Verslype, Chris, Prof, Tejpar, Sabine, Prof, Wildiers, Hans, Prof, de Haas, Sanne, PhD, Carmeliet, Peter, Prof, Scherer, Stefan J, MD, Van Cutsem, Eric, Prof

Volltext

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐pos... von Kim, Sung‐Bae, Wildiers, Hans, Krop, Ian E., Smitt, Melanie, Yu, Ron, Lysbet de Haas, Sanne, Gonzalez‐Martin, Antonio

Volltext

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III stu... von de Haas, Sanne L, Slamon, Dennis J, Martin, Miguel, Press, Michael F, Lewis, Gail D, Lambertini, Chiara, Prat, Aleix, Lopez-Valverde, Vanesa, Boulet, Thomas, Hurvitz, Sara A

Volltext

Promotion of sleep by targeting the orexin system in rats, dogs and humans von Jenck, François, Brisbare-Roch, Catherine, Dingemanse, Jasper, Koberstein, Ralf, Hoever, Petra, Aissaoui, Hamed, Flores, Susan, Mueller, Celia, Nayler, Oliver, van Gerven, Joop, de Haas, Sanne L, Hess, Patrick, Qiu, Changbin, Buchmann, Stephan, Scherz, Michael, Weller, Thomas, Fischli, Walter, Clozel, Martine

Volltext

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, rando... von Emens, Leisha A, Esteva, Francisco J, Beresford, Mark, Saura, Cristina, De Laurentiis, Michelino, Kim, Sung-Bae, Im, Seock-Ah, Wang, Yifan, Salgado, Roberto, Mani, Aruna, Shah, Jigna, Lambertini, Chiara, Liu, Haiying, de Haas, Sanne L, Patre, Monika, Loi, Sherene

Volltext

Markers of Response for the Antiangiogenic Agent Bevacizumab von LAMBRECHTS, Diether, LENZ, Heinz-Josef, DE HAAS, Sanne, CARMELIET, Peter, SCHERER, Stefan J

Volltext

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE von Loibl, Sibylle, Huang, Chiun-Sheng, Mano, Max S., Mamounas, Eleftherios P., Geyer, Charles E., Untch, Michael, Thery, Jean-Christophe, Schwaner, Ingo, Limentani, Steven, Loman, Niklas, Lübbe, Kristina, Chang, Jenny C., Hatschek, Thomas, Tesarowski, David, Song, Chunyan, Lysbet de Haas, Sanne, Boulet, Thomas, Lambertini, Chiara, Wolmark, Norman

Volltext

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial von VAN CUTSEM, Eric, DE HAAS, S. Anne, SHAH, Manish A, KANG, Yoon-Koo, OHTSU, Atsushi, TEBBUTT, Niall C, JIAN MING XU, WEI PENG YONG, LANGER, Bernd, DELMAR, Paul, SCHERER, Stefan J

Volltext

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2―Positive, Locally Advanced, or Metastatic Breast Cancer von MILLER, Kathy D, DIERAS, Véronique, DE HAAS, Sanne L, BURRIS, Howard A, HARBECK, Nadia, ANDRE, Fabrice, MAHTANI, Reshma L, GIANNI, Luca, ALBAIN, Kathy S, CRIVELLARI, Diana, LIANG FANG, MICHELSON, Glenn

Volltext

Orexin receptor antagonism: an ascending multiple-dose study with almorexant von Hoever, Petra, de Haas, Sanne L, Dorffner, Georg, Chiossi, Eleonora, van Gerven, Joop M, Dingemanse, Jasper

Volltext

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced bre... von Perez, Edith A, de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H, Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B, Burris, 3rd, Howard A, Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony

Volltext

Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial von Huang, Liang, Pang, Da, Yang, Hongjian, Li, Wei, Wang, Shusen, Cui, Shude, Liao, Ning, Wang, Yongsheng, Wang, Chuan, Chang, Yuan-Ching, Wang, Hwei-Chung, Kang, Seok Yun, Seo, Jae Hong, Shen, Kunwei, Laohawiriyakamol, Suphawat, Jiang, Zefei, Wang, Haiyan, Lamour, François, Song, Grace, Curran, Michelle, Duan, Chunzhe, Lysbet de Haas, Sanne, Restuccia, Eleonora, Shao, Zhimin

Volltext

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast... von Dang, Chau, Ewer, Michael S, Delaloge, Suzette, Ferrero, Jean-Marc, Colomer, Ramon, de la Cruz-Merino, Luis, Werner, Theresa L, Dadswell, Katherine, Verrill, Mark, Eiger, Daniel, Sarkar, Sriparna, de Haas, Sanne Lysbet, Restuccia, Eleonora, Swain, Sandra M

Volltext

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer von Harbeck, Nadia, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Gluz, Oleg

Volltext

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positi... von Perez, Edith A, de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H, Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B, Burris, 3rd, Howard A, Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony

Volltext

Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma von Boot, Johan D, de Haas, Sanne, Tarasevych, Svetlana, Roy, Christine, Wang, Lin, Amin, Dilip, Cohen, Judith, Sterk, Peter J, Miller, Barry, Paccaly, Anne, Burggraaf, Jacobus, Cohen, Adam F, Diamant, Zuzana

Volltext

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment von Oosting, Sjoukje F, Brouwers, Adrienne H, van Es, Suzanne C, Nagengast, Wouter B, Oude Munnink, Thijs H, Lub-de Hooge, Marjolijn N, Hollema, Harry, de Jong, Johan R, de Jong, Igle J, de Haas, Sanne, Scherer, Stefan J, Sluiter, Wim J, Dierckx, Rudi A, Bongaerts, Alfons H H, Gietema, Jourik A, de Vries, Elisabeth G E

Volltext

Subjective Sleep Disturbance in Patients with Partial Epilepsy: A Questionnaire‐based Study on Prevalence and Impact on Quality of Life von De Weerd, Al, De Haas, Sanne, Otte, Andreas, Trenité, Dorothée Kasteleijn‐Nolst, Van Erp, Gerard, Cohen, Adam, De Kam, Marieke, Van Gerven, Joop

Volltext